Friday, April 22, 2016

UPDATE 1-FDA staff forces advisory panel vote on Sarepta muscle drug

April 22 (Reuters) - Sarepta Therapeutics Inc's

muscle wasting drug got a new lease of life on Friday after

staff at the U.S. Food and Drug Administration made it necessary

that an independent panel...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)